December 10, 2007
Merck has agreed to pay $670 million to settle allegations that it violated the False Claims Act by engaging in nominal pricing fraud.
According to a December 4, 2007 article in the Corporate Crime Reporter, the company allegedly defrauded federal and state health care programs by offering to provide hospitals with, for example, its statin drug at a nominal cost if the hospital would agree to fill the majority of its statin prescriptions with that company’s drug.